Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial

References

• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.
   PubMed Web of Science ®Google Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302–308.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–928.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S111–S134.
   PubMed Web of Science ®Google Scholar
• McAllister DA, Read SH, Kerssens J, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation. 2018;138:2774–2786.
   PubMed Web of Science ®Google Scholar
• Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016;165:473–481.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S98–S110.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Xia C, Goud A, D’Souza J, et al. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Fail Rev. 2017;22:299–304.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139:351–361.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17:39.
   PubMed Web of Science ®Google Scholar
• Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the Cardiovascular Outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12:164–174.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Kahn SE, Johansen OE, et al. Effects of linagliptin vs glimepiride on major cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA. 2019. DOI:10.1001/jama.2019.13772.
   Web of Science ®Google Scholar
• Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–267.
   PubMed Web of Science ®Google Scholar
• Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28:1352–1361.
   PubMed Web of Science ®Google Scholar
• Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:653–661.
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65–74.
   PubMed Web of Science ®Google Scholar
• Dicembrini I, Montereggi C, Nreu B, et al. Pancreatitis and pancreatic cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;159:107981.
   PubMed Web of Science ®Google Scholar
• Abd El Aziz M, Cahyadi O, Meier JJ, et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22:699–704.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bethel MA, Green JB, et al. Pancreatic safety of sitagliptin in the TECOS study. Diabetes Care. 2017;40:164–170.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17:387–405.
   PubMed Web of Science ®Google Scholar
• Gamble JM, Donnan JR, Chibrikov E, et al. Comparative safety of dipeptidyl peptidase-4 inhibitors versus sulfonylureas and other glucose-lowering therapies for three acute outcomes. Sci Rep. 2018;8:15142.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company [Internet]. Glucophage (metformin hydrochloride) tablets, for oral use. Highlights of prescribing information. 2018. [cited 2019 Oct 23]. Available from: https://packageinserts.bms.com/pi/pi_glucophage.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. Drug safety communication (April 8, 2016): FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2016. [cited 2019 Oct 23]. Available from: https://www.fda.gov/media/96771/download
   Google Scholar
• Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:2099.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S135–S151.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2019. Issue with updates. Diabetes Care. 2019;42:S124–S128.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar